5-HT1D receptor drugs for Migraine
5 tracked 5-HT1D receptor drugs in the Migraine race. The class explanation lives on the 5-HT1D receptor page; the full indication pipeline across every mechanism is on the Migraine page.
4 approved / phase 41 preclinical / unstaged
Head-to-head evidence: Dihydroergotamine (Atzumi) vs Dihydroergotamine mesylate (Brekiya) · Dihydroergotamine (Atzumi) vs Dihydroergotamine mesylate (D.H.E. 45) · Dihydroergotamine (Atzumi) vs Dihydroergotamine mesylate (Migranal) · Dihydroergotamine (Atzumi) vs Dihydroergotamine mesylate/Dipyrone/Caffeine (Cefaliv)